• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cureus . A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination

tetano

tetano

Editor, Senior Moderator
Cureus


. 2021 May 15;13(5):e15035.
doi: 10.7759/cureus.15035.
A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination


Sérgio Brito[SUP] 1 [/SUP], Nuno Ferreira[SUP] 1 [/SUP], Sofia Mateus[SUP] 1 [/SUP], Manuela Bernardo[SUP] 2 [/SUP], Beatriz Pinto[SUP] 3 [/SUP], Ana Lourenço[SUP] 1 [/SUP], Fátima Grenho[SUP] 1 [/SUP]



Affiliations

Abstract

Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.

Keywords: autoimmune hemolytic anemia; covid-19 mrna vaccine; immune-mediated hemolysis; sars-cov-2; warm autoimmune hemolytic anemia.
 
You must log in or register to reply here.
Back
Top Bottom